Zelnorm, the drug for constipation-predominant IBS, has been withdrawn in the US. It has never been available in the UK, but I know it has helped a great deal of people in America and other countries as well, and IBS drugs are so thin on the ground anyway that this is really not good news.
It's also eerily reminiscent of the bizarre situation which surrounded the IBS-D drug Lotronex, which was approved and then withdrawn and then approved again after a campaign by IBS sufferers. Looks like we might have to start fighting again...
The reason given for the withdrawal is that the drug was linked in a retrospective review of the entire clinical database of Zelnorm patients to a higher risk of heart attacks, strokes and chest pain. The review compared the incidences of heart problems in patients taking Zelnorm to the number of incidences in patients taking the placebo. This is the first time I had heard of any major concerns over cardiovascular side effects from Zelnorm, although there had been concerns over ischemic colitis.
In a statement on their homepage, the manufacturers Novartis say this:
"The data, which were reviewed by independent experts, showed that events occurred in 13 out of 11,614 patients treated with Zelnorm/Zelmac (0.11%), compared to one case in 7,031 placebo-treated patients (0.01%). All patients affected had pre-existing cardiovascular disease and/or CV risk factors."
Now, 13 out of 11,614 patients seems to me to be a fantastically tiny number, but apparently it is high enough to make the link statistically significant, and therefore the FDA asked for the drug's withdrawal.
I'll update this entry as I get more info.
Update: The FDA have issued a statement which includes advice to anyone currently taking Zelnorm...
"FDA is currently advising patients who are using Zelnorm to contact their health care providers to discuss treatment alternatives. Patients who are taking Zelnorm should seek emergency medical care if they experience severe chest pain, shortness of breath, dizziness, sudden onset of weakness or difficulty walking or talking, or other symptoms of a heart attack or stroke."
Now that sounds like a very alarming statement, and obviously anyone who is worried should contact their doctor, but the fact remains that only 13 out of 11,614 patients reported heart issues, so this is not a reason to panic.
The FDA also say the following:
"FDA will work with Novartis to allow access to Zelnorm as an investigational drug for patients with no other treatment options where the benefits may outweigh the risks. FDA has also indicated to Novartis the possibility of considering limited re-introduction of Zelnorm at a later date if a population of patients can be identified in which the benefits of the drug outweigh the risks."
The "benefits outweighing the risks" argument is the main source of contention in this kind of situation. Almost all drugs have side effects, and when we are talking about non-fatal conditions such as IBS, the severity of those side effects is weighed against the perceived severity of the medical condition itself. I think it would be fair to say that the impact of IBS is often under-rated, which may mean that the FDA are too quick to pull drugs for IBS because they believe that we can live pretty well without them...
For more info see the Novartis website or the FDA website.
Recent Comments